Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: Final results of the LL02 trialof the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Andrea Ferrario, Francesco Merli, Stefano Luminari, Caterina Stelitano, Donato Mannina, Mario Russo, Patrizio Mazza, Luigi Marcheselli, Maria Cecilia Goldaniga, Massimo Federico, Luca Baldini

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogenous subset whose treatment has been poorly investigated. In this context we have evaluated the efficacy and safety of combined fludarabine and cyclophosphamide (FC) upfront therapy. Sixty-three patients with advanced INFL were enrolled in the study. Therapy consisted in FC combination (25 and 250 mg/m2, i.v., respectively, for three consecutive days) every 28 days for six courses. After histological review, 61 patients (36 men, median age 64 years, range 40-70 years) were evaluated (22 small lymphocytic, 11 lymphoplasmacytic, 25 marginal zone and 3 CD5-negative non-Hodgkin lymphomas not otherwise specified). Further two patients were excluded for lack of essential data; six patients were withdrawn before the third cycle because of WHO grade III and IV toxicity. At the final evaluation, the overall response rate was 83% with 40.7% of complete remission. Intention-to-treat analysis showed that at the median follow-up of 36 months, overall survival, progression-free survival and failure-free survival were respectively 78%, 60% and 46%; remission duration among the 49 patients achieving complete remission/partial remission at the end of treatment was 65% (44-78) without significant differences between the main histotypes. The most frequent grade III and IV toxic events were haematological (neutropaenia 34%, anaemia 18% and thrombocytopaenia 11%) and infectious (10%). FC is effective for advanced untreated INFL. Early deaths and haematological toxicity suggest careful patient selection and monitoring.

Original languageEnglish
Pages (from-to)323-330
Number of pages8
JournalAnnals of Hematology
Volume90
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Cyclophosphamide
Lymphoma
B-Lymphocytes
Non-Hodgkin's Lymphoma
Therapeutics
Intention to Treat Analysis
Survival
Poisons
Physiologic Monitoring
Patient Selection
Disease-Free Survival
Anemia
fludarabine
Safety

Keywords

  • Chemotherapy
  • Cyclophosphamide
  • Fludarabine
  • Indolent non-follicular lymphomas

ASJC Scopus subject areas

  • Hematology

Cite this

Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas : Final results of the LL02 trialof the Gruppo Italiano per lo Studio dei Linfomi (GISL). / Ferrario, Andrea; Merli, Francesco; Luminari, Stefano; Stelitano, Caterina; Mannina, Donato; Russo, Mario; Mazza, Patrizio; Marcheselli, Luigi; Goldaniga, Maria Cecilia; Federico, Massimo; Baldini, Luca.

In: Annals of Hematology, Vol. 90, No. 3, 03.2011, p. 323-330.

Research output: Contribution to journalArticle

Ferrario, Andrea ; Merli, Francesco ; Luminari, Stefano ; Stelitano, Caterina ; Mannina, Donato ; Russo, Mario ; Mazza, Patrizio ; Marcheselli, Luigi ; Goldaniga, Maria Cecilia ; Federico, Massimo ; Baldini, Luca. / Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas : Final results of the LL02 trialof the Gruppo Italiano per lo Studio dei Linfomi (GISL). In: Annals of Hematology. 2011 ; Vol. 90, No. 3. pp. 323-330.
@article{529c0d0c87d54dce80b87766a0771871,
title = "Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: Final results of the LL02 trialof the Gruppo Italiano per lo Studio dei Linfomi (GISL)",
abstract = "Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogenous subset whose treatment has been poorly investigated. In this context we have evaluated the efficacy and safety of combined fludarabine and cyclophosphamide (FC) upfront therapy. Sixty-three patients with advanced INFL were enrolled in the study. Therapy consisted in FC combination (25 and 250 mg/m2, i.v., respectively, for three consecutive days) every 28 days for six courses. After histological review, 61 patients (36 men, median age 64 years, range 40-70 years) were evaluated (22 small lymphocytic, 11 lymphoplasmacytic, 25 marginal zone and 3 CD5-negative non-Hodgkin lymphomas not otherwise specified). Further two patients were excluded for lack of essential data; six patients were withdrawn before the third cycle because of WHO grade III and IV toxicity. At the final evaluation, the overall response rate was 83{\%} with 40.7{\%} of complete remission. Intention-to-treat analysis showed that at the median follow-up of 36 months, overall survival, progression-free survival and failure-free survival were respectively 78{\%}, 60{\%} and 46{\%}; remission duration among the 49 patients achieving complete remission/partial remission at the end of treatment was 65{\%} (44-78) without significant differences between the main histotypes. The most frequent grade III and IV toxic events were haematological (neutropaenia 34{\%}, anaemia 18{\%} and thrombocytopaenia 11{\%}) and infectious (10{\%}). FC is effective for advanced untreated INFL. Early deaths and haematological toxicity suggest careful patient selection and monitoring.",
keywords = "Chemotherapy, Cyclophosphamide, Fludarabine, Indolent non-follicular lymphomas",
author = "Andrea Ferrario and Francesco Merli and Stefano Luminari and Caterina Stelitano and Donato Mannina and Mario Russo and Patrizio Mazza and Luigi Marcheselli and Goldaniga, {Maria Cecilia} and Massimo Federico and Luca Baldini",
year = "2011",
month = "3",
doi = "10.1007/s00277-010-1067-1",
language = "English",
volume = "90",
pages = "323--330",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas

T2 - Final results of the LL02 trialof the Gruppo Italiano per lo Studio dei Linfomi (GISL)

AU - Ferrario, Andrea

AU - Merli, Francesco

AU - Luminari, Stefano

AU - Stelitano, Caterina

AU - Mannina, Donato

AU - Russo, Mario

AU - Mazza, Patrizio

AU - Marcheselli, Luigi

AU - Goldaniga, Maria Cecilia

AU - Federico, Massimo

AU - Baldini, Luca

PY - 2011/3

Y1 - 2011/3

N2 - Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogenous subset whose treatment has been poorly investigated. In this context we have evaluated the efficacy and safety of combined fludarabine and cyclophosphamide (FC) upfront therapy. Sixty-three patients with advanced INFL were enrolled in the study. Therapy consisted in FC combination (25 and 250 mg/m2, i.v., respectively, for three consecutive days) every 28 days for six courses. After histological review, 61 patients (36 men, median age 64 years, range 40-70 years) were evaluated (22 small lymphocytic, 11 lymphoplasmacytic, 25 marginal zone and 3 CD5-negative non-Hodgkin lymphomas not otherwise specified). Further two patients were excluded for lack of essential data; six patients were withdrawn before the third cycle because of WHO grade III and IV toxicity. At the final evaluation, the overall response rate was 83% with 40.7% of complete remission. Intention-to-treat analysis showed that at the median follow-up of 36 months, overall survival, progression-free survival and failure-free survival were respectively 78%, 60% and 46%; remission duration among the 49 patients achieving complete remission/partial remission at the end of treatment was 65% (44-78) without significant differences between the main histotypes. The most frequent grade III and IV toxic events were haematological (neutropaenia 34%, anaemia 18% and thrombocytopaenia 11%) and infectious (10%). FC is effective for advanced untreated INFL. Early deaths and haematological toxicity suggest careful patient selection and monitoring.

AB - Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogenous subset whose treatment has been poorly investigated. In this context we have evaluated the efficacy and safety of combined fludarabine and cyclophosphamide (FC) upfront therapy. Sixty-three patients with advanced INFL were enrolled in the study. Therapy consisted in FC combination (25 and 250 mg/m2, i.v., respectively, for three consecutive days) every 28 days for six courses. After histological review, 61 patients (36 men, median age 64 years, range 40-70 years) were evaluated (22 small lymphocytic, 11 lymphoplasmacytic, 25 marginal zone and 3 CD5-negative non-Hodgkin lymphomas not otherwise specified). Further two patients were excluded for lack of essential data; six patients were withdrawn before the third cycle because of WHO grade III and IV toxicity. At the final evaluation, the overall response rate was 83% with 40.7% of complete remission. Intention-to-treat analysis showed that at the median follow-up of 36 months, overall survival, progression-free survival and failure-free survival were respectively 78%, 60% and 46%; remission duration among the 49 patients achieving complete remission/partial remission at the end of treatment was 65% (44-78) without significant differences between the main histotypes. The most frequent grade III and IV toxic events were haematological (neutropaenia 34%, anaemia 18% and thrombocytopaenia 11%) and infectious (10%). FC is effective for advanced untreated INFL. Early deaths and haematological toxicity suggest careful patient selection and monitoring.

KW - Chemotherapy

KW - Cyclophosphamide

KW - Fludarabine

KW - Indolent non-follicular lymphomas

UR - http://www.scopus.com/inward/record.url?scp=79951682605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951682605&partnerID=8YFLogxK

U2 - 10.1007/s00277-010-1067-1

DO - 10.1007/s00277-010-1067-1

M3 - Article

C2 - 20848104

AN - SCOPUS:79951682605

VL - 90

SP - 323

EP - 330

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 3

ER -